Stock Taper 
CUVL
$7.74
▼ DOWN 0.77% (-0.06)
KEY STATISTICS
Market Cap$390.31 M
52w High$9.00
52w Low$5.98
Dividend Yield—
Frequency—
P/E—
Volume206
Shares Out.50.43M
COMPANY
LEADERSHIP
CHIEF EXECUTIVE
Philippe Jacques Wolgen
ABOUT
SECTOR
Healthcare
WENT PUBLIC
July 13, 2026
METHOD OF GOING PUBLIC
Dual Listing
UPCOMING EARNINGS
DateAug 27, 2026
DayThursday
Rev. Est.$42.23M
AUG
27
THU
PRICE
$7.74 ▼ DOWN 0.77% (−$0.06)About Clinuvel Pharmaceuticals Ltd.
https://www.clinuvel.com ↗Clinuvel Pharmaceuticals develops treatments for genetic and life-threatening disorders, including its lead drug SCENESSE for erythropoietic protoporphyria, and offers photocosmetic products globally.
INDUSTRY
Medical - Pharmaceuticals
A PRODUCT CLINUVEL PHARMACEUTICALS LTD. IS KNOWN FOR
SCENESSE® (afamelanotide 16mg)
SCENESSE® by Clinuvel Pharmaceuticals is the world's first systemic photoprotective drug, approved to prevent phototoxicity in adults with the rare genetic disorder erythropoietic protoporphyria (EPP).
